Stock Spotlights Archives - Page 13 of 18

ThursdayAug 25, 2022 1:36 pm

TinyGemsBreaks – QSAM Biosciences Inc. (QSAM) Receives ‘Marketable Advantage’ Toward Manufacturing, Supply Chain of CycloSam(R)

QSAM Biosciences (OTCQB: QSAM) recently received a key patent for its exclusive radiopharmaceutical drug candidate, CycloSam(R), from the U.S. Patent & Trademark Office. “The patent protects how CycloSam is formulated and prepared, namely by using a nonradioactive kit that can be delivered and stored local to the administration site and provides for high purity in an efficient, facile and reproducible process at lower costs… The scope of this patent is fairly broad in that it not only protects the use of QSAM’s primary radioisotope, Samarium-153 (Sm-153), but also several other radioactive materials used in commercialized radiopharmaceuticals such as Lutetium-177 (Lu-177)…

WednesdayAug 24, 2022 1:15 pm

TinyGemsBreaks – Golden Matrix Group Inc. (NASDAQ: GMGI) Providing Industry Leading, Turnkey B2B iGaming, Esports Solutions

Golden Matrix (NASDAQ: GMGI), a developer and licensor of online gaming platforms, systems and gaming content, continues to leverage technological advances and incorporate them into its turnkey B2B solutions for online gambling operators. “Recent technological advances have made online gambling easier, more convenient and more enjoyable for some users when compared to a physical casino experience… GMGI appears to be on trend with the movement of users online and away from physical gambling, which has not recovered from COVID-19 business restrictions,” a recent article reads. “Golden Matrix leads the industry in providing turnkey B2B iGaming and Esports solutions for operators…

TuesdayAug 23, 2022 1:26 pm

TinyGemsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Continues Priority to Advance Clinical Development Program for Berubicin

CNS Pharmaceuticals (NASDAQ: CNSP) is focused on advancing its clinical program for treating glioblastoma (“GBM”), a brain cancer that has no present cure and few treatment options for patients. The most aggressive primary brain tumor, GBM affects approximately 13,000 new patients each year in the United States with an average survival time of less than one year post diagnosis. “The company’s lead drug candidate is a novel anthracycline named Berubicin that has set itself apart from other potential therapies because of its apparent ability to cross the blood-brain barrier with central nervous system uptake,” reads a recent article. “CNS Pharmaceuticals…

MondayAug 22, 2022 1:15 pm

TinyGemsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Stands to Gain Substantial Revenue Through Licensing of DehydraTECH(TM)

Lexaria Bioscience Corp. (NASDAQ: LEXX) recently announced that Japanese Licensee, Premier Wellness Science Co. Ltd., officially launched the first generation of its new cannabidiol (“CBD”) products under the brand, “Ko.” “The exclusive rights between Premier and Lexaria are subject to two previously issued licenses for using DehydraTECH technology in Japan for non-pharmaceutical cannabinoid products… Under the terms of the license agreement with Lexaria, Premier purchased rights to the company’s DehydraTECH technology for use in the non-pharmaceutical market for CBD and hemp ingredients in oral liquid and non-liquid product form, including topical, hair care, lip care, and cosmetics,” a recent article…

FridayAug 19, 2022 2:30 pm

TinyGemsBreaks – Golden Matrix Group Inc. (NASDAQ: GMGI) Leveraging GM-X Solution, Robust Portfolio to Exploit New Era of Online Gambling Sector’s Growth

Golden Matrix (NASDAQ: GMGI), a developer and licensor of online gaming platforms, systems and gaming content, is well placed to exploit the growth of the online gambling sector. “The advent of online gaming as well as the rapid uptake witnessed within the realm of metaverse gaming has attracted a host of platforms to the sector… There are now several thousand platforms vying for market share within an increasingly crowded space. A number of those companies are seeking to focus their efforts on marketing, opting to procure their operational systems and gaming portfolios from third-party providers such as Golden Matrix Group.…

WednesdayAug 17, 2022 2:36 pm

TinyGemsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH Capable of Delivering APIs More Efficiently by Overcoming Food Effect

Lexaria Bioscience Corp. (NASDAQ: LEXX) recently announced the allowance of a new patent in Japan, the fourth to be granted in that country and the 26th worldwide. “Entitled Lipophilic Active Agent Infused Compositions with Reduced Food Effect, this is the first patent issued from Lexaria’s seventh patent family and refers to tetrahydrocannabinol (‘THC’). The new patent acknowledges DehydraTECH(TM)’s ability to deliver active pharmaceutical ingredients (‘APIs’) more efficiently, in a process known as absorption, regardless of the presence of food in the gastrointestinal system. Ordinarily, food impacts drug absorption by physically interacting with drugs, altering the pH, stimulating bile flow, slowing…

WednesdayAug 17, 2022 2:17 pm

TinyGemsBreaks – Energy Fuels Inc.’s (NYSE American: UUUU) (TSX: EFR) White Mesa Mill ‘Meets Definition of Domestic Clean-Energy Infrastructure’

Energy Fuels (NYSE American: UUUU) (TSX: EFR) is a leading U.S.-based producer of uranium and vanadium and an emerging producer of rare earth elements (“REE”) products. “After concerns surfaced about the impact a Utah uranium mill [Energy Fuel’s White Mesa Mill] might have on the surrounding water sources, an op-ed piece in the Denver Post reported that there is ‘no evidence that implies the tailings cells are leaking or contaminating groundwater.’ That assessment aligns with what Energy Fuels has said all along; safety and environmental protection are top priorities for the company,” a recent article reads. The piece contains excerpts…

WednesdayAug 17, 2022 1:51 pm

TinyGemsBreaks – Cepton Inc. (NASDAQ: CPTN) Driving State-of-the-Art Solutions

Cepton (NASDAQ: CPTN) is an innovator pioneering high-performance Micro Motion Technology (“MMT(R)”) lidar solutions. The company recently selected Fabrinet (NYSE: FN), a leader specializing in precision optical, electro-optical, sophisticated electronic PCBA, and electro-mechanical process technologies, to produce its flagship automotive-grade Vista(R)-X90 lidar. The partnership could expedite Cepton’s efforts toward mass-market commercialization of high-performance, high-quality lidar solutions. “The Vista(R)-X90 lidar features Cepton’s patented MMT(R) technology configured to deliver scalable lidar solutions with a superior balance between performance, reliability and cost, as well as Cepton’s proprietary lidar engine ASIC, designed for optical illumination control, detection and signal processing. Vista(R)-X90 will be deployed…

FridayAug 12, 2022 1:30 pm

TinyGemsBreaks – Aditxt Inc. (NASDAQ: ADTX) Looking to Solve Medical Challenge in Immune Responses

Aditxt (NASDAQ: ADTX) has sought to address a medical conundrum: approximately 50% of all transplanted organs are rejected by the host’s body within 10-12 years despite a wide array of medical innovations in recent years. This highlights the critical need for a practical, cost-effective solution to harmful immune responses. Aditxt is looking to solve this medical problem “through the creation of immune reprogramming technologies, which are being developed to retrain the immune system to induce tolerance to transplanted organs, self-tissues (autoimmune diseases) and allergens,” a recent article reads. “While still at a pre-clinical stage, ADi(TM) (Apoptotic DNA Immunotherapy), the company’s…

FridayAug 12, 2022 12:40 pm

TinyGemsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Positioning Berubicin Clinical Development Program for Success

CNS Pharmaceuticals (NASDAQ: CNSP) is currently recruiting patients for a phase II study evaluating the efficacy and safety of Berubicin, its lead drug candidate for treating glioblastoma multiforme (“GBM”), the most aggressive, deadly and treatment-resistant type of cancer that forms in the brain. Recently, the company announced that the FDA had approved an amendment to the study’s protocol, boosting its Berubicin clinical development program. “The amendment expands eligibility for its potentially pivotal study to patients who have received additional treatments as part of the first-line therapy,” explains a recent article. “The key objectives of the amendment, according to CNS Pharmaceuticals…

Spotlighting undiscovered companies with enormous upside potential.

Contact us: (310) 299-1717

Breaks Categories: Stock Spotlights